Immatics, a biotech company working on promising cell-based immunotherapies for solid cancers, has a promising TCR-engineered ...

Immatics has vaulted into phase 3 on the strength of early-stage data. The biotech is gearing up to start a pivotal trial of ...

Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Immatics (IMTX – Research Report) on October 11 and set a price target ...

Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development ...

Immatics (IMTX) has released an update. Immatics has reported promising updated Phase 1b clinical data for its ACTengine ...

On Thursday, Immatics N.V. (NASDAQ:IMTX) stock is trading lower after the company commenced an underwritten public offering ...

We recently published a list of 10 Best Biotech Stocks To Buy Under $20. In this article, we are going to take a look at ...

Immatics shares were down 10% to $9.95 after the company began a proposed $150 million underwritten public offering of its ordinary shares.

German cancer specialist Immatics has priced a $150 million public offering with Jefferies, BofA Securities, and Leerink as ...

Piper Sandler started coverage on shares of Immatics (NASDAQ:IMTX – Free Report) in a research report report published on Monday, MarketBeat reports. The firm issued an overweight rating and a $ ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the ...